Skip to main content
Premium Trial:

Request an Annual Quote

Synthetic Genomics, Avoca Ink Deal for Natural Astaxanthin

NEW YORK (GenomeWeb) – Avoca and Synthetic Genomics today announced a supply agreement to extract and commercialize natural astaxanthin from algae strains developed by SGI.

The agreement also gives Avoca the exclusive rights to sell in North America products based on SGI-produced astaxanthin. Avoca's parent firm, Pharmachem Laboratories, will market and sell the products.

Natural astaxanthin is a supplement with health benefits associated with its antioxidant and anti-inflammatory properties, Avoca said. However, the difficult nature of producing the supplement has meant supplies of it have fallen short of demand.

SGI has developed a production process for natural astaxanthin from a phototropic source and has shown capabilities to manufacture it on a commercial scale. Products covered by the deal are being developed by SGI's Genovia Bio business unit, which has responsibility for developing and commercializing algal-based food, chemical, and fuel products.

Financial and other terms of the deal were not disclosed.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.